Enterin Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $14.2M
Latest Deal Amount
  • Investors
  • 3

Enterin General Information

Description

Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displace α-synuclein aggregates and restore normal signaling between the gut and the brain, thereby improving the quality of life of patients with Parkinson's disease and other neurodegenerative conditions.

Contact Information

Website
www.enterininc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2005 Market Street
  • Suite 3125
  • Philadelphia, PA 19103
  • United States

Enterin Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Enterin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 14-Sep-2020 $14.2M 000.00 00000 Completed Clinical Trials - Phase 2
4. Debt - PPP 28-Apr-2020 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 28-Jan-2019 000.00 000.00 00000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 10-Jul-2017 $12.7M $12.7M 000.00 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Startup
To view Enterin’s complete valuation and funding history, request access »

Enterin Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 1,865,223 $0.000100 5% $4.56 $4.56 1x $4.56 8.11%
Series A-1 2,846,620 $0.000100 5% $2.91 $2.91 1x $2.91 12.38%
To view Enterin’s complete cap table history, request access »

Enterin Executive Team (7)

Name Title Board Seat Contact Info
Jay Brammer Chief Executive Officer & Board Member
David McCullough Chief Executive Officer
Denise Barbut MD Co-Founder, Co-Chairman, President & Chief Medical Officer
Michael Zasloff Ph.D Co-Founder, Chief Scientific Officer & Co-Chairman
Stuart Barlow Chief Financial Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Enterin Board Members (5)

Name Representing Role Since
Jay Brammer Enterin Chief Executive Officer & Board Member 000 0000
Mark Finn Scientia Ventures Board Member 000 0000
Michael Zasloff Ph.D Enterin Co-Founder, Chief Scientific Officer & Co-Chairman 000 0000
Richard Propper MD Self Board Member 000 0000
Richard Warburg Ph.D Scientia Ventures Board Member 000 0000
To view Enterin’s complete board members history, request access »

Enterin Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enterin Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gibraltar Remembrance Services Asset Manager Minority 000 0000 000000 0
Scientia Ventures Venture Capital Minority 000 0000 000000 0
Science Center Accelerator/Incubator 000 0000 000000 0
To view Enterin’s complete investors history, request access »

Ready to get started?

Request a free trial